Prevalence of Metabolic Syndrome in Psoriasis and Levels of Interleukin-6 and Tumor Necrosis Factor-α in Psoriasis Patients with Metabolic Syndrome: Indian Tertiary Care Hospital Study

Abstract

**Background:** Psoriasis is a chronic inflammatory multisystem disease, found to be associated with metabolic syndrome (MS) and increased levels of cytokines. To evaluate the prevalence of MS in psoriasis and to determine the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in psoriasis patients with MS. **Methods:** Observational study on 334 psoriasis patients and 230 controls. MS was diagnosed by the presence of three or more criteria of original, revised, and modified National Cholesterol Education Program’s Adult Treatment Panel III (NCEP ATP III). **Results:** MS was significantly more common in psoriasis patients than in controls (multivariate odds ratio [95% confidence interval] of original NCEP ATP III = 5.73 [2.99–10.99], revised NCEP ATP III = 4.44 [2.43–8.10], and modified NCEP ATP III = 6.00 [3.43–10.52]). Higher prevalence of abdominal obesity (66.2% vs. 47%, P < 0.001), hypertriglyceridemia (40.4% vs. 29.6%, P = 0.009), systolic blood pressure (BP) ≥130 mmHg (25.1% vs. 7.4%, P < 0.001), diastolic BP ≥85 mmHg (30.2% vs. 12.2%, P < 0.001), and fasting plasma glucose ≥100 mg/dl (17.4% vs. 9.1%, P = 0.005) among psoriasis patients as compared to controls. Mean (standard deviation) values of IL-6 and TNF-α were 76.7 (73.9) pg/ml and 234.3 (273.9) in subgroup of psoriasis patients with MS (n = 42), significantly higher than the normal population (P < 0.0001). **Conclusion:** MS is more common in psoriasis. IL-6 and TNF-α is significantly higher in psoriasis patients with MS, signifying their role in pathogenesis of psoriasis and MS.

**Keywords:** Comorbidities, cytokines, metabolic syndrome, psoriasis

Introduction

Psoriasis is a chronic inflammatory genetically determined multisystem disease affecting about 0.44%–2.8% of the Indian population.[1] Interaction between T lymphocytes, mast cells, macrophages, and dendritic cells involving various cytokines including interleukins (ILs) such as IL-1, IL-2, IL-6, interferon-γ (INF-γ), and tumor necrosis factor-α (TNF-α) in psoriasis lead to the systemic manifestations of the disease.[2] Psoriasis has been found to be associated with obesity, metabolic syndrome (MS),[3,4] and cardiovascular (CVS) comorbidities.[5,6] Using the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria, study done by Gisondi et al. found that MS was significantly more common in psoriasis patients than in controls (30.1% vs. 20.6%, odds ratio [OR]: 1.65; 95% confidence interval [CI] - 1.16–2.35; P = 0.005.) after the age of 40 years.[3] National Health and Nutrition Examination Survey (NHANES) reported 39.9% prevalence of MS in psoriasis cases and 23.5% among controls.[4]

MS is associated with chronic low-grade inflammation involving cytokines IL-1, IL-2, IL-6, INF-γ, and TNF-α, led to increased risk of atherosclerotic CVS disease (CVD) and Type 2 diabetes mellitus (DM).[7,8]

Currently, there are few published studies done in the Indian population with regard to the prevalence of MS in psoriasis. Our study is a part of larger study in which we evaluate the efficacy and safety of insulin sensitizers in patients with psoriasis having MS, divided into topical[9] and systemic cohort (unpublished data). We did study not only the prevalence of MS in psoriasis as compared to controls but also evaluated the differences in the characteristics among psoriasis patients with or without MS. Secondary objective was to study the

Surjit Singh, Sunil Dogra1, Nusrat Shafiq2, Anil Bhansali3, Samir Malhotra2

Department of Pharmacology, AIIMS, Jodhpur, Rajasthan, Departments of 1Dermatology Venereology Leprology, 2Pharmacology and 3Endocrinology, PGIMER, Chandigarh, India

Received: 30 August, 2016. Accepted: 14 March, 2017.

Address for correspondence:
Dr. Surjit Singh, Department of Pharmacology, AIIMS, Jodhpur - 342 005, Rajasthan, India.
E-mail: sehmy_ss@yahoo.com

Access this article online
Website: www.jabmr.org
DOI: 10.4103/ijabmr.IJABMR_330_16

Quick Response Code:
How to cite this article: Singh S, Dogra S, Shafiq N, Bhansali A, Malhotra S. Prevalence of metabolic syndrome in psoriasis and levels of Interleukin-6 and tumor necrosis factor-α in psoriasis patients with metabolic syndrome: Indian Tertiary Care Hospital study. Int J App Basic Med Res 2017;7:169-75.
levels of IL-6 and TNF-α in psoriasis cases having MS. Therefore, we endeavored to evaluate the prevalence of MS in psoriasis patients attending tertiary care hospital using original,[10] revised,[8,11] and modified NCEP ATP III criteria.[12]

Methods
The study was conducted at our institute, from January 2010 to June 2011. The study was approved by Institute Ethics Committee, Postgraduate Institute of Medical Education and Research, Chandigarh, India. All subjects satisfying the inclusion-exclusion criteria were enrolled in the study after taking written informed consent.

Study design
For assessment of point prevalence of MS in patients with psoriasis, a case of psoriasis was defined as a clinical diagnosis of psoriasis regardless of age sex or severity of disease. Controls were defined as patients with dermatoses other than psoriasis having no known association with MS attending dermatological outpatient department. Primary end point was to study the prevalence of MS in a case-control study in psoriasis patients. Secondary objective was to study the levels of IL-6 and TNF-α in psoriasis cases having MS.

MS assessment was done by the presence of three or more criteria of the modified NCEP ATP III:[12] waist circumference >90 cm in men and >80 cm in women, hypertriglyceridemia ≥150 mg/dl, high-density lipoprotein (HDL) cholesterol <40 mg/dl in males and <50 mg/dl in females, blood pressure (BP) ≥130/85 mmHg, and fasting plasma glucose (FPG) ≥110 mg/dl. The assessment of MS by original and revised NCEP ATP III criteria was also done. Original NCEP ATP III criteria are similar to modified NCEP ATP III except abdominal obesity (waist circumference >102 cm in men and >88 cm in women).[10] While revised NCEP ATP III criteria are similar to original NCEP ATP III except for blood glucose level cutoff is defined as ≥100 mg/dl.[8,11]

Statistical analysis
Data were expressed as mean ± standard deviation (SD) (95% CIs), numbers (percentages), and median (interquartile range). Baseline characteristics between psoriasis and controls were compared using an independent t-test for numerical variables and Chi-square test for categorical variables.

The prevalence of MS was calculated according to the presence of psoriasis. Logistic regression was performed to evaluate the association between psoriasis and the presence of MS and the results were expressed as OR. First, logistic regression was done without adjustment and then with adjustment of the covariates that are known to affect the prevalence for MS. Age, sex, body mass index (BMI) are known to affect the prevalence of MS. Smoking status and alcohol intake were also entered as covariates because of their known association with insulin sensitivity, diabetes, and weight. Since, serum levels of glucose, triglycerides, HDL cholesterol, waist circumference and BP are all part of the definition of the MS and were therefore excluded from the multivariate model. The frequency of MS features between psoriasis and controls was compared using Pearson Chi-square test. The difference in prevalence of MS between psoriasis and controls among different age groups was done by Kolmogorov–Smirnov Z-test. Spearman’s rho and Pearson correlation were used to study the correlation between MS and categorical variables and numerical variables, respectively.

Results
The baseline characteristics of psoriasis and control population were shown in Table 1. The mean age of participants in psoriasis patients was 39.1 years and in control was 35.4 years. Mean age, prevalence of DM, hypertension (HTN), history of alcohol intake and smoking, BMI, and total cholesterol were significantly higher in individuals with psoriasis compared to controls [Table 1]. Similarly, parameters of MS, namely, waist circumference, FPG, serum triglyceride levels, systolic BP (SBP), and diastolic BP (DBP) were significantly higher in psoriasis cases as compared to controls [Table 1].

The prevalence of MS according to original, revised, and modified NCEP ATP III criteria was 30.8%, 32.6%, and 40.9% among individual with psoriasis and 8.7%, 10.9%, and 12.2% among controls, respectively [Table 2]. The OR for psoriasis patients with MS as compared to controls was 4.81 (95% CI - 2.85–8.13), 4.05 (95% CI - 2.50–6.55), and 5.04 (95% CI - 3.19–7.96) on univariate analysis and 5.73 (95% CI - 2.99–10.99), 4.44 (95% CI - 2.43–8.10), and 6.00 (95% CI - 3.43–10.52) after adjustment for age, sex, BMI, smoking status, and alcohol intake for original, revised, and modified NCEP ATP III criteria, respectively.

The prevalence of individual components of the MS according to the presence of psoriasis is shown in Table 3. Waist circumference, hypertriglyceridemia, high SBP, high DBP, high FPG (revised and original NCEP ATP III Criteria) were significantly more prevalent in psoriasis as compared to controls. Higher percentage of individuals with psoriasis meets the modified NCEP ATP III criteria for MS and increased percentage of an individual with psoriasis has three or more than three components of MS [Figure 1]. Significantly higher prevalence of MS was seen in all age groups in psoriasis patients as compared to controls [Figure 2].

Psoriasis patients with MS had significantly higher mean age, of onset, and total duration of disease as compared to psoriasis patients without MS [Table 4]. Remission, joint involvement, and history of HTN and DM were more prevalent in psoriasis patients with MS as compared
Singh, et al.: Prevalence of metabolic syndrome

### Table 1: Baseline characteristics of psoriasis patients and controls

| Baseline characteristics          | Psoriasis (n=334) | Controls (n=230) | P (two-sided) |
|-----------------------------------|-------------------|-----------------|---------------|
| Age (years), mean±SD              | 39.1±14.0         | 35.4±14.7       | 0.003         |
| Male/females, n (%)               | 209/125 (63.7/46.3) | 146/84 (63.5/46.5) | 0.859         |
| DM, n (%)                         | 25 (7.6)          | 3 (1.3)         | <0.001        |
| HTN, n (%)                        | 61 (18.6)         | 12 (5.2)        | <0.001        |
| CAD, n (%)                        | 1 (0.3)           | 2 (0.9)         | 0.571         |
| Alcohol, n (%)                    | 75 (22.9)         | 33 (14.3)       | 0.022         |
| Smoking, n (%)                    | 59 (18)           | 20 (8.7)        | 0.003         |
| Vegetarian, n (%)                 | 188 (57.3)        | 133 (57.8)      | 0.730         |
| BMI (kg/m²), mean±SD              | 24.8±5.1          | 23.1±4.4        | <0.001        |
| WC (cm), mean±SD                  | 92.8±13.4         | 87.4±11.4       | <0.001        |
| Waist: hip ratio, mean±SD         | 0.94±0.07         | 0.92±0.06       | <0.001        |
| FPG (mg/dl), mean±SD              | 89.7±21.2         | 85.7±11.4       | 0.009         |
| Total cholesterol (mg/dl), mean±SD | 176.8±38.0       | 168.1±35.6      | 0.008         |
| Triglycerides (mg/dl), mean±SD    | 151.2±78.0        | 133.3±52.5      | 0.003         |
| HDL (mg/dl), mean±SD              | 45.7±9.3          | 45.8±10.7       | 0.921         |
| LDL (mg/dl), mean±SD              | 111.9±30.6        | 106.6±30.1      | 0.056         |
| SBP (mmHg), mean±SD               | 125.8±14.5        | 119.5±11.8      | <0.001        |
| DBP (mmHg), mean±SD               | 80.4±8.8          | 77.7±7.5        | <0.001        |

DM: Diabetes mellitus; HTN: Hypertension; CAD: Coronary artery disease; BMI: Body mass index; FPG: Fasting plasma glucose; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; SD: Standard deviation; WC: Waist circumference

### Table 2: Prevalence of metabolic syndrome in psoriasis and controls

| MS parameters | Psoriasis, n (%) | Controls, n (%) | Unadjusted OR (95% CI) | P | Multivariate OR (95% CI) | P |
|---------------|-----------------|----------------|------------------------|---|--------------------------|---|
| Total         | n=334           | n=230          |                        |   |                          |   |
| Original NCEP ATPIII[10] | 101 (30.8)     | 20 (8.7)       | 4.81 (2.85-8.13)       | <0.001 | 5.73 (2.99-10.99)       | <0.001 |
| Revised NCEP ATPIII[8,11] | 107 (32.6)     | 25 (10.9)      | 4.05 (2.50-6.55)       | <0.001 | 4.44 (2.43-8.10)       | <0.001 |
| Modified NCEP ATPIII[12] | 134 (40.9)     | 28 (12.2)      | 5.04 (3.19-7.96)       | <0.001 | 6.00 (3.43-10.52)      | <0.001 |
| Male          | n=209           | n=145          |                        |   |                          |   |
| Original NCEP ATPIII[10] | 49 (23.4)      | 7 (4.8)        | 7.10 (2.95-17.07)      | <0.001 | 7.22 (2.62-19.88)      | <0.001 |
| Revised NCEP ATPIII[8,11] | 54 (25.8)      | 11 (7.6)       | 4.70 (2.31-9.60)       | <0.001 | 4.72 (1.97-11.34)      | 0.001  |
| Modified NCEP ATPIII[12] | 77 (36.8)      | 15 (10.3)      | 5.06 (2.76-9.25)       | <0.001 | 5.80 (2.77-12.15)      | <0.001 |
| Female        | n=125           | n=85           |                        |   |                          |   |
| Original NCEP ATPIII[10] | 52 (41.6)      | 13 (15.3)      | 3.95 (1.98-7.86)       | <0.001 | 4.31 (1.84-10.13)      | 0.001  |
| Revised NCEP ATPIII[8,11] | 53 (42.4)      | 14 (16.5)      | 3.73 (1.90-7.33)       | <0.001 | 3.93 (1.72-8.98)      | <0.001 |
| Modified NCEP ATPIII[12] | 57 (45.6)      | 13 (15.3)      | 4.64 (2.33-9.23)       | <0.001 | 5.26 (2.27-12.18)      | <0.001 |

Multivariate OR refers to ORs obtained using a logistic regression model after adjustment for age, sex, BMI, smoking status, alcohol. Age divided into five groups - <30, 31-40, 41-50, 51-60, >60, BMI divided into <25, >25. BMI: Body mass index; ORs: Odds ratios; CI: Confidence interval; NCEP ATPIII: National Cholesterol Education Program’s Adult Treatment Panel III; MS: Metabolic syndrome

### Table 3: Prevalence of individual metabolic abnormalities of the metabolic syndrome (modified National Cholesterol Education Program’s Adult Treatment Panel III criteria) in psoriasis and control groups

| MS parameters | Psoriasis (n=334), n (%) | Controls (n=230), n (%) | Unadjusted OR (95% CI) (Mantel-Haenszel) | P | Multivariate OR (95% CI) | P |
|---------------|--------------------------|-------------------------|-----------------------------------------|---|--------------------------|---|
| WC (males >90 cm, females >80 cm) | 221 (66.2) | 108 (47) | 2.21 (1.57-3.11) | <0.001 | 2.33 (1.62-3.35)       | <0.001 |
| Hypertriglyceridemia (TG ≥150 mg/dl) | 135 (40.4) | 68 (29.6) | 1.62 (1.13-2.31) | 0.009 | 1.63 (1.13-2.35)      | 0.009 |
| Low HDL (males <40, females <50 mg/dl) | 148 (44.3) | 92 (40.0) | 1.17 (0.83-1.65) | 0.361 | 1.2 (0.82-1.74)      | 0.350 |
| High SBP (≥130 mmHg) | 84 (25.1) | 17 (7.4) | 4.2 (2.42-7.31) | <0.001 | 4.52 (2.57-7.95)      | <0.001 |
| High DBP (≥85 mmHg) | 101 (30.2) | 26 (12.2) | 3.13 (1.98-4.95) | <0.001 | 3.47 (2.16-5.57)      | <0.001 |
| High FPG, original (≥110 mg/dl) | 31 (9.3) | 4 (1.7) | 5.78 (2.01-16.61) | 0.001 | 5.69 (1.95-16.61)      | 0.001 |
| High FPG, revised (≥100 mg/dl) | 58 (17.4) | 21 (9.1) | 2.09 (1.23-3.56) | 0.006 | 2.16 (1.26-3.72)      | 0.005 |

Multivariate OR refers to ORs obtained using a logistic regression model after adjustment for age, sex, BMI. Age divided into five groups - <30, 31-40, 41-50, 51-60, >60, BMI divided into <25, >25. BMI: Body mass index; ORs: Odds ratios; CI: Confidence interval; MS: Metabolic syndrome; WC: Waist circumference
to the absence of MS. All parameters of MS (waist circumference, serum triglycerides, HDL cholesterol, SBP, DBP, and FPG), BMI, waist to hip ratio, total cholesterol, and low-density lipoprotein cholesterol had significantly higher mean values except HDL cholesterol (significantly lower) in psoriasis patients with MS as compared to psoriasis patients without MS. Mean (SD) values of IL-6 and TNF-α were 76.7 (±73.9) pg/ml and 234.3 (±273.9) in subgroup of psoriasis patients with MS (n = 42), significantly higher than the mean values present in normal population ([IL-6 = 1.79 ± 2.03 and TNF-α = 2.74 ± 0.94], P < 0.0001 for both IL-6 and TNF-α).

**Discussion**

A hospital-based case–control study showed that MS was significantly more common in psoriasis patients than in controls (30.1% vs. 20.6%, OR: 1.65; 95% CI - 1.16–2.35; P = 0.005) after the age of 40 years.[3] Psoriasis patients who had hyperleptinemia were found to be female (P < 0.001) and manifest obesity (P = 0.002) and MS (P = 0.003).[13] Recently, a study done by The NHANES had estimated 39.9% prevalence of MS among psoriasis cases as compared to 23.5% among controls.[4] Comparison of prevalence of MS in cases and controls in our study with regard to NHANES, hospital-based case–control study is shown in Table 5.

The prevalence of MS in those with psoriasis was nearly three times as compared to controls (12.2% prevalence), and excess prevalence remained substantial after adjustment for covariates such as age, sex, BMI, smoking status, and alcohol. Our results were similar to the findings of a study done by Langan *et al*.[14] Zindanci *et al*.[15] Madanagobalane *et al*.[16] Nisa and Qazi,[17] and Ali *et al*.[18] These findings may partially explain the increased risk of CVS morbidity and mortality among psoriasis patients. Large population-based cohort studies in the United Kingdom demonstrated increased risk of myocardial infarction, stroke and CVS mortality in patients with severe psoriasis.[4,19] Recently, three meta-analyses of CVD in psoriasis had supported these findings.[20–22] Females with psoriasis demonstrated a 63% increased risk of future diabetes compared to controls. Gelfand *et al*. found higher mortality risk for arterial and venous thrombosis along with myocardial infarction especially in young patients with severe psoriasis. Finally, patients with severe psoriasis were found to die about 3–4 years earlier than patients without psoriasis.[23] As these CVS outcomes are known complications of the MS, its increased prevalence in psoriasis may contribute to the CVS complications, as observed in psoriasis patients. MS is a strong predictor of CVDs, diabetes and stroke and significantly increases the risk of CVS mortality.[24] MS also increases the risk of all-cause and colon cancer mortality.[25]

We have found that the prevalence of MS is significantly higher in psoriasis patients as compared to controls among all age groups and prevalence increases with increasing age. A very consistent finding among different studies is that prevalence of MS is strictly age dependent, increasing sharply after the age of 60.[26] The prevalence of MS in psoriasis patients had a direct correlation with disease duration, the results similar to the case–control study done by Gisondi *et al*., which found that the prevalence of MS after the age of 40 was significantly higher in psoriasis patients compared with controls and it directly correlates to duration of psoriasis.[3] Significantly more number of controls individuals without MS was smokers as compared to MS with psoriasis. This may be because of the increased number of individuals who quit smoking on physician advice in psoriasis patients with MS.

In this study, we observed that abdominal obesity and disturbances in lipid profiles were the most important factors contributing to the increased prevalence of MS. These were followed by low HDL, BP, and FPG levels. NHANES
Table 4: Descriptive characteristics of psoriasis patients with and without metabolic syndrome (Modified NCEP ATPIII criteria)

| Characteristics                  | Psoriasis patients with MS (n=134) | Psoriasis patients without MS (n=200) | Chi-Square value*/Mean difference (95%CI)* P |
|----------------------------------|-----------------------------------|--------------------------------------|---------------------------------------------|
| Age (years), (Mean±SD)           | 47.6±12.5                         | 33.4±11.9                            | 14.2 (11.5-16.8)*                           <0.001* |
| Male/Females, n (%)              | 77/57 (57.5/42.5)                 | 132/68 (66/34)                       | 2.497*                                      | 0.114  |
| Age of onset (years), (Mean±SD)  | 38.8±13.4                         | 26.9±12.0                            | 11.8 (8.9-14.5)*                           <0.001* |
| Total duration of disease (years), (Mean±SD) | 8.9±9.4                         | 6.5±6.9                             | 2.4 (0.6-4.2)*                            <0.001* |
| Seasonal Exacerbation, n (%)     | 88 (65.7)                         | 121 (60.5)                           | 0.916*                                      | 0.338  |
| Seasonal improvement, n (%)       | 86 (64.2)                         | 114 (57)                             | 1.721*                                      | 0.190  |
| Remission, n (%)                 | 102 (76.1)                        | 128 (64)                             | 5.496*                                      | 0.019* |
| Nail involvement, n (%)          | 91 (67.9)                         | 119 (59.5)                           | 2.432*                                      | 0.119  |
| Joint involvement, n (%)         | 31 (23.1)                         | 19 (9.5)                             | 11.718*                                    | 0.001* |
| DM, n (%)                        | 22 (16.4)                         | 3 (1.5)                              | 25.787*                                    | <0.001* |
| HTN, n (%)                       | 51 (38.1)                         | 10 (5)                               | 58.747*                                    | <0.001* |
| Family H/O Psoriasis, n (%)      | 14 (10.4)                         | 28 (14)                              | 0.921*                                      | 0.337  |
| Alcohol, n (%)                   | 35 (26.1)                         | 40 (20)                              | 1.726*                                      | 0.190  |
| Smoking, n (%)                   | 15 (11.2)                         | 44 (22)                              | 6.442*                                      | 0.011* |
| Vegetarian, n (%)                | 78 (58.2)                         | 110 (55)                             | 0.336*                                      | 0.562  |
| BMI (kg/m²), (Mean±SD)           | 27.5±4.2                         | 23.0±4.8                             | 4.5 (3.5-5.5)*                            <0.001* |
| Waist circumference (cm), (Mean±SD) | 101.1±10.1                      | 87.3±12.4                            | 13.9 (11.3-16.4)*                          <0.001* |
| Waist: Hip                       | 0.98±0.06                        | 0.91±0.07                            | 0.06 (0.05-0.08)                           <0.001* |
| PASI, (Mean±SD)                  | 15.2±6.9                         | 16.5±8.5                             | 1.3 (1.4-3.9)*                            0.535  |
| ESI, (Mean±SD)                   | 6.3±1.8                          | 6.1±1.9                              | 0.3 (-0.1-0.7)*                            0.185  |
| PGA, (Mean±SD)                   | 4.0±1.3                          | 3.8±1.4                              | 0.3 (-0.0-0.6)*                            0.080  |
| FPGi (mg/dl), (Mean±SD)          | 99.9±27.7                        | 82.8±10.9                            | 17.2 (12.9-21.4)*                          <0.001* |
| Total Cholesterol (mg/dl), (Mean±SD) | 192.8±42.1                      | 166.1±30.9                           | 26.7 (18.9-34.6)*                          <0.001* |
| Triglycerides (mg/dl), (Mean±SD) | 187.3±103.6                      | 126.9±39.1                           | 60.4 (44.5-76.2)*                          <0.001* |
| HDL (mg/dl), (Mean±SD)           | 43.9±10.0                        | 47.2±9.1                             | -3.2 (-1.1-3.3)*                           0.003* |
| LDL (mg/dl), (Mean±SD)           | 118.9±35.5                       | 106.9±26.2                           | 11.9 (5.3-18.5)*                           <0.001* |
| SBP (mmHg), (Mean±SD)            | 134.3±14.7                       | 120.1±11.2                           | 14.2 (11.4-16.9)*                          <0.001* |
| DBP (mmHg), (Mean±SD)            | 85.8±8.6                         | 76.7±6.9                             | 9.1 (7.4-10.7)*                            <0.001* |

*Chi-square test was used to compare categorical variables, †Student’s t-test was used to compare numerical variables, ‡Statistically significant difference between two groups. SD: Standard deviation; DBP: Diastolic blood pressure; SBP: Systolic blood pressure; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; DM: Diabetes mellitus; HTN: Hypertension; FPG: Fasting plasma glucose; ESI: Elastase-specific inhibitor; PASI: Psoriasis Area Severity Index; PGA: Psoriasis Global Assessment; MS: Metabolic syndrome; WC: Waist circumference; OR: Odds ratio; CI: Confidence interval

Obesity is associated with abnormalities in the development of psoriasis and MS as well as other inflammatory diseases such as atherosclerosis and asthma. Furthermore, the evidence is accumulating that similar to other chronic inflammatory diseases such as systemic lupus erythematosus and rheumatoid arthritis, psoriasis may, in fact, be a true systemic inflammatory process, intimately linked with atherosclerosis.[4,29,30] We had observed a significant increase in the levels of IL-6 and TNF-α in psoriasis patients with MS as compared to the normal population.

Similar to results for the frequency distribution of the MS components according to the presence of psoriasis in NHANES study,[4] significant more number of patients had three or more components of MS in our study.

The close association between psoriasis and MS could be explained by shared genetic risk loci, as indicated in recent studies[4] and hospital-based case–control study[3] also found that MS in psoriasis was primarily associated with obesity and high triglyceride levels. A recent meta-analysis reported an increased prevalence of traditional CVS risk factors, but not all studies found an association of psoriasis with diabetes.[27] As our study was a cross-sectional type of study, the directionality of association between psoriasis and MS could not be determined. We cannot conclude what happened first, psoriasis or MS.

We have found that psoriasis patients have a significantly higher BMI and waist circumference as compared to controls. Evidence suggests that insulin resistance plays prime role in the development of MS. Evidence from cohort studies points that obesity is associated with future development of psoriasis.[28] Obese individuals are prone to proinflammatory state, and adipose tissue is a rich source of inflammatory mediators known as adipokynes. Furthermore, central obesity is associated with abnormal levels of IL-6 and TNF-α, and as these mediators have well known role in the pathogenesis of psoriasis, it can be concluded that central obesity is the central determinant in the development of psoriasis and MS as well as other inflammatory diseases such as atherosclerosis and asthma. Furthermore, the evidence is accumulating that similar to other chronic inflammatory diseases such as systemic lupus erythematosus and rheumatoid arthritis; psoriasis may, in fact, be a true systemic inflammatory process, intimately linked with atherosclerosis.[6,29,30]
Table 5: Comparison of prevalence of metabolic syndrome in cases and control in the National Health and Nutrition Examination Survey, hospital-based case-control study by Gisondi et al., UK-based study by Landan, study by Zindaci et al., Madanagobalane et al. and our study

| MS          | Original NCEP ATP III[10] | Revised NCEP ATP III[8,11] | Multivariate OR* (95% CI) | P       |
|-------------|---------------------------|---------------------------|---------------------------|---------|
|             | Psoriasis (%)              | Controls (%)              | Psoriasis (%)              | Controls (%) |                                                 |          |
| Our study   |                           |                           |                           |          |
| Total       | 30.8                       | 8.7                       | 32.6                      | 10.9     | 4.44 (2.43-8.10)‡                          | <0.001‡ |
| Male        | 23.4                       | 4.8                       | 25.8                      | 7.6      | 4.72 (1.97-11.34)‡                         | <0.001‡ |
| Female      | 41.6                       | 15.3                      | 42.4                      | 16.5     | 3.93 (1.72-8.98)‡                         | <0.001‡ |
| NHANES[6]   |                           |                           |                           |          |
| Total       | 31.4                       | 17.1                      | 39.9                      | 23.5     | 1.96 (1.02-3.77)‡                         | <0.001‡ |
| Male        | 28.8                       | 18.8                      | 30.6                      | 26.6     | 1.08 (0.45-2.58)‡                         |          |
| Female      | 33.7                       | 15.4                      | 47.9                      | 20.4     | 2.80 (1.12-6.96)‡                         |          |
| Case–control study[31] | | | | | 1.65 (1.16-2.35)‡ | 0.005‡ |
| Langan et al.[14] | | | | | 1.41 (1.31-1.51)‡ |          |
| Zindaci et al.[15] | | | | | 2.94 (1.40-6.19)‡ | <0.01‡ |
| Madanagobalane et al.[16] | | | | | 44.1 | 30 |
| Total       |                           |                           |                           |          |

*Multivariate OR for revised NCEP ATP III criteria; † MS criteria by International diabetes foundation; ‡ Statistically significant difference between two groups. MS: Metabolic syndrome; NHANES: National Health and Nutrition Examination Survey; NCEP ATP III: National Cholesterol Education Program’s Adult Treatment Panel III; OR: Odds ratio; CI: Confidence interval.

Genome-wide association studies. For example, CDKAL1 has been associated with both psoriasis and Type II DM, and PTPN22 has been found to be associated with many diseases, including psoriasis and Type I diabetes.[7]

The strengths and limitations of our study need to be commented on. This study was done in a tertiary care hospital in India, catering a large Northern area, so the results of the study are likely to be generalizable to at least northern part of India. Our study had suggested a statistically significant difference in the prevalence of MS in psoriasis patients as compared to controls which were maintained when male and females psoriasis patients were compared with respective controls.

First limitation, a sample size of our study was relatively small for an epidemiological study for the estimation of prevalence of MS in psoriasis. Our study was not designed to assess the correlation between psoriasis and MS, i.e., whether psoriasis preceded MS or MS preceded psoriasis, which can be answered in prospective cohort studies with adequate sample size.

Conclusion

The increased prevalence of MS among the individuals with psoriasis along with statistically significant higher levels of IL-6 and TNF-α, impose increased risk of CVDs, diabetes and stroke. With lifestyle changes in the Indian population, it is of importance that MS should be prevented in psoriasis so as to decrease the morbidity and mortality and improve the quality of life.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References

1. Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol 2010;76:595-601.
2. Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl 2012;89:24-8.
3. Gisondi P, Tessari G, Conti A, Piaiserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br J Dermatol 2007;157:68-73.
4. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: Results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol 2011;147:419-24.
5. Ni C, Chiu MW. Psoriasis and comorbidities: Links and risks. Clin Cosmet Investig Dermatol 2014;7:119-32.
6. Mosca S, Gargiulo P, Balato N, Di Costanzo L, Parente A, Paolillo S, et al. Ischemic cardiovascular involvement in psoriasis: A systematic review. Int J Cardiol 2015;178:191-9.
7. Li Y, Liao W, Chang M, Schrodi SJ, Bui N, Catanese JJ, et al. Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22. J Invest Dermatol 2009;129:626-34.
8. Grundy SM, Brewer HB Jr., Cleeman JI, Smith SC Jr., Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
9. Singh S, Bhansali A. Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). BMC Dermatol. 2016;16:12.
10. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
11. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
12. Misra A, Wasir JS, Pandey RM. An evaluation of candidate definitions of the metabolic syndrome in adult Asian Indians. Diabetes Care. 2005;28:398-403.
13. Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144:1571-5.
14. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 Pt 1):556-62.
15. Zindanci I, Albayrak O, Kavala M, Kocaturk E, Can B, Sudogun S, et al. Prevalence of metabolic syndrome in patients with psoriasis. ScientificWorldJournal. 2012;2012:312465.
16. Madanagobalane S, Anandan S. Prevalence of metabolic syndrome in South Indian patients with psoriasis vulgaris and the relation between disease severity and metabolic syndrome: a hospital-based case-control study. Indian J Dermatol. 2012;57:353-7.
17. Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol. 2010;76:662-5.
18. Ali NM, Kuruvilla M, Unnikrishnan B. Psoriasis and metabolic syndrome: a case control study. Indian J Dermatol Venereol Leprol. 2014;80:255-7.
19. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31:1000-6.
20. Tobin AM, Veale DJ, Fitzgerald O, Rogers S, Collins P, O'Shea D, et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol. 2010;37:1386-94.
21. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2:e000062.
22. Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72:211-6.
23. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-41.
24. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005;165:2644-50.
25. Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J Pathol. 2006;169:1505-22.
26. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Circadiol Rev. 2005;13:322-7.
27. Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol. 2010;24 Suppl 2:23-30.
28. Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr. 2008;88:1242-7.
29. Tegl H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6:772-83.
30. Alexandroff AB, Pauriah M, Lang CC, Struthers AD, Armstrong DJ. Atherosclerosis as a systemic feature of psoriasis. Clin Exp Dermatol. 2011;36:451-2.